Maze Therapeutics logo

Maze Therapeutics

MAZE | NASDAQ
Chart Builder DCF Calculator
$33.90
-$0.43 (-1.25%)
At close: Nov 16, 2026, 4:00 PM ET
$33.58
-$0.32 (-0.94%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.25%

Rating

Updated: Nov 16, 2026
32.6
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #726/1021 (Top 71%)

Key Statistics

Market Data

Market Cap $2.06B
1D Range
33.50 36.29
52W Range
22.39 51.84

Valuation (TTM)

PE -11.81
PB 4.81
EV/EBITDA -11.41

Valuation (NTM)

Forward PE N/A
Forward PEG 1.21
Price Target $75.00
Loading financial charts...

Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead progr...

Sector Healthcare
Industry Biotechnology
Employees 141
IPO Date Jan 31, 2025
Fiscal Year January - December

Latest News

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

7 days ago · globenewswire.com

Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know

13 days ago · zacks.com

Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know
Maze Therapeutics to Participate in Upcoming Investor Conferences

14 days ago · globenewswire.com

Maze Therapeutics to Participate in Upcoming Investor Conferences
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

29 days ago · zacks.com

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

29 days ago · zacks.com

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

1 month ago · globenewswire.com

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

2 months ago · fool.com

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Maze Therapeutics to Participate in Three Upcoming Investor Conferences

3 months ago · globenewswire.com

Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

3 months ago · seekingalpha.com

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist
Maze Therapeutics Announces Appointments to Its Board of Directors

3 months ago · globenewswire.com

Maze Therapeutics Announces Appointments to Its Board of Directors

Earnings

Next Earnings
Mar 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$75.00
Upside
+121.24%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.